ReviewCardiovascular diabetology2019

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Jean-Charles Fruchart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.